跳至主要内容
临床试验/NCT04263402
NCT04263402Unknown4 期

An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia

Tongji Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
100
试验地点
1
主要终点
Rate and time of entering the critical stage

研究概览

简要总结

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1.Meet the definition of severe pneumonia(Comply with any of the followings):
  • Shortness of breath,RR≥30 bpm;
  • In a resting state:SPO2≤93%;
  • PaO2/FiO2≤300mmHg.
  • 2.2019-nCoV nucleic acid test was positive.
  • 3.CT of the lung conformed to the manifestation of viral pneumonia.

排除标准

  • dying state (i.e. survival time is less than 24 hours);
  • progressive malignant tumor with life expectancy less than 6 months;
  • immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs)
  • underlying diseases requiring long-term glucocorticoid treatment in the past 6 months or short-term glucocorticoid therapy in the past 4 weeks;
  • patients with glucocorticoid taboos

研究组 & 干预措施

Methylprednisolone(40~80mg/d)

Experimental

干预措施: Methylprednisolone (Drug)

Methylprednisolone(<40mg/d)

Experimental

干预措施: Methylprednisolone (Drug)

结局指标

主要结局

Rate and time of entering the critical stage

时间窗: day 7

the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.

Rate of disease remission

时间窗: day 7

For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2\>93% or PaO2/FiO2 \>300mmHg.

次要结局

  • Rate of normal tempreture(day 7)
  • Rate of respiratory symptom remission(day 7)
  • Rate of laboratory indicator recovery(day 7)
  • Rate of lung imaging recovery(day 7)
  • Rate of undetectable viral RNA(day 7)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Qin Ning

Professor

Tongji Hospital

研究点 (1)

Loading locations...

相似试验